Clinical News
View All >>Chronic HCV Patients do not Have Significant Gut Microbiota Differences
12 minutes ago
By Kenny Walter
The investigators found minor differences in the microbial community structure between the control group and the chronic HCV group.
Cannabinoids Improve Sleep in the First and Largest Cannabinoid Clinical Trial
12 hours ago
By Giuliana Grossi
A majority of individuals who received one of the various cannabinoid products experienced a significant improvement in sleep quality and duration.
Aaron Kowalski, PhD: Creating a Cycle of Improvement for Type 1 Diabetes
14 hours ago
By Connor Iapoce
100 years after the discovery of insulin, the T1D Index may provide a foundational understanding of what steps need to be taken to both improve lives and reduce the incidence of T1D.
Aaron Kowalski, PhD: Connecting the Dots with the Type 1 Diabetes Index
16 hours ago
By Connor Iapoce
With the launch of the T1D index, the global burden of the disease and its impact is better understood. Dr. Kowalski joins to dig deeper into its importance and his personal connection to T1D.
Challenges with Current Treatments and Emerging Treatments for C. difficile Infection (CDI)
20 hours ago
By Paul Feuerstadt, MD
Drs Chopra and Feuerstadt summarize challenges with current treatments and discuss live biotherapeutic products that are being studied for recurrent C difficile infection (rCDI).
Novel Pain Therapy Addresses the Complex Pathway of Painful Diabetic Neuropathy
September 27, 2022
By Giuliana Grossi
Dr. Craig Granowitz of Lexicon Pharmaceuticals details the success of the LX9211 clinical trial for painful diabetic neuropathy and the unique study design.
Patients With Vitiligo Report Varied Severe Symptoms Based on Skin Tone
September 08, 2022
By Tim Smith
Large numbers of vitiligo patients around the world have reported differing outcomes, with darker skin types expressing the more significant severity, according to new findings.
Ruxolitinib Beneficial Across Demographics of Patients with Vitiligo
September 08, 2022
By Tim Smith
Research presented at EADV 2022 sees positive outcomes with the targeted therapy for patients of varied backgrounds with vitiligo.
Promising Data from InPedILD Phase 3 Trial Revealed at ERS Congress 2022
September 08, 2022
By Giuliana Grossi
Novel insights into the risk-benefit profile of nintedanib in children and adolescents with fibrosing interstitial lung disease (ILD) were provided by late-breaking data presented at ERS 2022 regarding the InPedILD clinical trial.
September 28, 2022 7:32 PM
By Biree Andemariam, MD
September 28, 2022 7:16 PM
By Biree Andemariam, MD
September 28, 2022 1:44 PM
By Paul Feuerstadt, MD
September 28, 2022 10:00 AM
By Tim Smith
September 27, 2022 10:00 PM
By Connor Iapoce
September 27, 2022 9:00 PM
By Connor Iapoce
September 27, 2022 8:00 PM
By Kenny Walter
September 27, 2022 6:30 PM
By Giuliana Grossi
September 27, 2022 6:00 PM
By Tim Smith
September 27, 2022 4:00 PM
By Kenny Walter
September 27, 2022 3:00 PM
By Tim Smith
September 27, 2022 12:58 PM
By Giuliana Grossi
